Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys

A recombinant adenovirus serotype 5 (rAd5) vector-based vaccine for HIV-1 has recently failed in a phase 2b efficacy study in humans1, 2. Consistent with these results, preclinical studies have demonstrated that rAd5 vectors expressing SIV Gag failed to reduce peak or setpoint viral loads following...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jinyan, O’Brien, Kara L., Lynch, Diana M., Simmons, Nathaniel L., La Porte, Annalena, Riggs, Ambryice M., Abbink, Peter, Coffey, Rory T., Grandpre, Lauren E., Seaman, Michael S., Landucci, Gary, Forthal, Donald N., Montefiori, David C., Carville, Angela, Mansfield, Keith G., Havenga, Menzo J., Pau, Maria G., Goudsmit, Jaap, Barouch, Dan H.
Formato: Texto
Lenguaje:English
Publicado: 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614452/
https://www.ncbi.nlm.nih.gov/pubmed/18997770
http://dx.doi.org/10.1038/nature07469

Ejemplares similares

Ejemplares similares